{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:08:33Z","timestamp":1780096113279,"version":"3.54.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.isci.2025.112806","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T19:51:42Z","timestamp":1748721102000},"page":"112806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hypoimmune CD19 CAR T cells treat allogeneic mice with features of spontaneous systemic lupus erythematosus"],"prefix":"10.1016","volume":"28","author":[{"given":"Xiaomeng","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari G.","family":"Olroyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Friera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin B.","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Deuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7696-6229","authenticated-orcid":false,"given":"Sonja","family":"Schrepfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2025.112806_bib1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.112806_bib2","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.112806_bib3","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.112806_bib4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.112806_bib5","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s43018-021-00241-5","article-title":"Engineering enhanced CAR T-cells for improved cancer therapy","volume":"2","author":"Milone","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.isci.2025.112806_bib6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.112806_bib7","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"Muller","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.112806_bib8","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.isci.2025.112806_bib9","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.isci.2025.112806_bib10","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.112806_bib11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.112806_bib12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.isci.2025.112806_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.stem.2024.03.006","article-title":"Therapeutic intersections: Expanding benefits of CD19 CAR T cells from cancer to autoimmunity","volume":"31","author":"Sosnoski","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.isci.2025.112806_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104590","article-title":"Are we ready for CD19-targeted CAR T-cell therapies in MS?","volume":"70","author":"Giovannoni","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.isci.2025.112806_bib15","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.112806_bib16","first-page":"1361","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Sci. Technol. Humanit."},{"key":"10.1016\/j.isci.2025.112806_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111492","article-title":"The HIP mouse and all of its organs are completely invisible to allogeneic immune cells","volume":"28","author":"Hu","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.isci.2025.112806_bib18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jama.1966.03100040091025","article-title":"NZB\/NZW mice as a model of systemic lupus erythematosus","volume":"195","author":"Dubois","year":"1966","journal-title":"JAMA"},{"key":"10.1016\/j.isci.2025.112806_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2025.112806_bib20","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41467-023-37785-2","article-title":"Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice","volume":"14","author":"Hu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.112806_bib21","first-page":"234","article-title":"Endpoints for mouse abdominal tumor models: refinement of current criteria","volume":"59","author":"Paster","year":"2009","journal-title":"Comp. Med."},{"key":"10.1016\/j.isci.2025.112806_bib22","article-title":"Inflammatory cytokines in systemic lupus erythematosus","volume":"2011","author":"Ohl","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.isci.2025.112806_bib23","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1111\/j.1523-1755.2005.09408.x","article-title":"The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population","author":"Gansevoort","year":"2005","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.isci.2025.112806_bib24","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1159\/000334955","article-title":"The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB\/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture","volume":"120","author":"Hainz","year":"2012","journal-title":"Nephron Exp. Nephrol."},{"key":"10.1016\/j.isci.2025.112806_bib25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1046\/j.1365-2249.1998.00632.x","article-title":"Aminoguanidine reduces glomerular inducible nitric oxide synthase (iNOS) and transforming growth factor-beta 1 (TGF-beta1) mRNA expression and diminishes glomerulosclerosis in NZB\/W F1 mice","volume":"113","author":"Yang","year":"1998","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.isci.2025.112806_bib26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0065-2776(08)60514-3","article-title":"MHC class I-deficient mice","volume":"55","author":"Raulet","year":"1994","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.isci.2025.112806_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.immuni.2011.11.013","article-title":"alphabeta T cell receptors that do not undergo major histocompatibility complex-specific thymic selection possess antibody-like recognition specificities","volume":"36","author":"Tikhonova","year":"2012","journal-title":"Immunity (Camb., Mass.)"},{"key":"10.1016\/j.isci.2025.112806_bib28","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.stem.2025.03.004","article-title":"Progress and challenges in developing allogeneic cell therapies","volume":"32","author":"Deuse","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.isci.2025.112806_bib29","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200839","article-title":"The SIRPalpha-CD47 immune checkpoint in NK cells","volume":"218","author":"Deuse","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2025.112806_bib30","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","article-title":"Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients","volume":"37","author":"Deuse","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2025.112806_bib31","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022091118","article-title":"Hypoimmune induced pluripotent stem cell-derived cell therapeutics treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice","volume":"118","author":"Deuse","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.112806_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg5794","article-title":"Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice","volume":"15","author":"Hu","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2025.112806_bib33","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41587-023-01784-x","article-title":"Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques","volume":"42","author":"Hu","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2025.112806_bib34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.stem.2024.02.001","article-title":"Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate","volume":"31","author":"Hu","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.isci.2025.112806_bib35","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1084\/jem.148.5.1198","article-title":"Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains","volume":"148","author":"Andrews","year":"1978","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2025.112806_bib36","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/art.1780210909","article-title":"Etiology and pathogenesis of a spontaneous lupus-like syndrome in mice","volume":"21","author":"Dixon","year":"1978","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.isci.2025.112806_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000199","article-title":"Mouse models of lupus: what they tell us and what they don't","volume":"5","author":"Richard","year":"2018","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.isci.2025.112806_bib38","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418761697","article-title":"B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets","volume":"11","author":"Forsthuber","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.isci.2025.112806_bib39","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.isci.2025.112806_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135081","article-title":"Bortezomib Plus Continuous B Cell Depletion Results in Sustained Plasma Cell Depletion and Amelioration of Lupus Nephritis in NZB\/W F1 Mice","volume":"10","author":"Khodadadi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.112806_bib41","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/rheumatology\/kex395","article-title":"Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register","volume":"57","author":"McCarthy","year":"2018","journal-title":"Rheumatology (Oxf.)"},{"key":"10.1016\/j.isci.2025.112806_bib42","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.4049\/jimmunol.1101629","article-title":"An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus","volume":"187","author":"Ahuja","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2025.112806_bib43","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.isci.2025.112806_bib44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/eji.1830180221","article-title":"The half-lives of serum immunoglobulins in adult mice","volume":"18","author":"Vieira","year":"1988","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.isci.2025.112806_bib45","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/s41590-022-01345-5","article-title":"Heterogeneous plasma cells and long-lived subsets in response to immunization, autoantigen and microbiota","volume":"23","author":"Liu","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.isci.2025.112806_bib46","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1074-7613(00)80541-5","article-title":"Humoral immunity due to long-lived plasma cells","volume":"8","author":"Slifka","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2025.112806_bib47","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4049\/jimmunol.180.1.361","article-title":"Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice","volume":"180","author":"DiLillo","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2025.112806_bib48","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1073\/pnas.0800555105","article-title":"Maintenance of the plasma cell pool is independent of memory B cells","volume":"105","author":"Ahuja","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.112806_bib49","doi-asserted-by":"crossref","first-page":"15178","DOI":"10.1073\/pnas.0505539102","article-title":"Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease","volume":"102","author":"Yazawa","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.112806_bib50","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2014-02-555169","article-title":"A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow","volume":"125","author":"Mei","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.112806_bib51","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.112806_bib52","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1084\/jem.20040168","article-title":"Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB\/W mice","volume":"199","author":"Hoyer","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2025.112806_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1476859","article-title":"CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.112806_bib54","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00281-013-0413-5","article-title":"Immunopathology of lupus nephritis","volume":"36","author":"Anders","year":"2014","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.isci.2025.112806_bib55","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.kint.2016.05.017","article-title":"A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis","volume":"90","author":"Anders","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.isci.2025.112806_bib56","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.isci.2025.112806_bib57","first-page":"890","article-title":"Factors associated with poor outcomes in patients with lupus nephritis","volume":"14","author":"Contreras","year":"2005","journal-title":"Lupus (Basingstoke)"},{"key":"10.1016\/j.isci.2025.112806_bib58","first-page":"1563","article-title":"Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure","volume":"33","author":"Faurschou","year":"2006","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.isci.2025.112806_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.112806_bib60","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.isci.2025.112806_bib61","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2025.112806_bib62","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.isci.2025.112806_bib63","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.112806_bib64","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1073\/pnas.90.9.3913","article-title":"Mice lacking major histocompatibility complex class I and class II molecules","volume":"90","author":"Grusby","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225010673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225010673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:01:07Z","timestamp":1777946467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004225010673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2589004225010673"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2025.112806","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypoimmune CD19 CAR T cells treat allogeneic mice with features of spontaneous systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2025.112806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112806"}}